Effectiveness and safety of dupilumab for the treatment of prurigo nodularis in a French multicenter adult cohort of 16 patients

Abstract

The notion that it is related to M. lepromatosis may be true according to some authors. However, others showed that the correlation is not that strong, looking at leprosy clinical types in different countries 6 ; M. lepromatosis may resemble M. leprae in causing different manifestations depending on the host immunity. 2 From the group around Rea and Modlin, Maria Achoa reported at the World Congress Dermatology in Milano that of their Mexican patients with lepra bonita, the majority was indeed infected with M. lepromatosis, while some had a single M. leprae infection or a mixed infection. Whether M. lepromatosis affects the internal organs more than M. leprae is yet to be proven. The difference in the type of infection may in part account for clinical and geographical variabilities associated with leprosy infection; however, according to our opinion, the survival of the bacilli in the environment and the socioeconomic factors are relatively more important. For the practising dermatologist, the bacilli causing leprosy are of academic interest only. The treatment is the same, and it is the resistance to therapy that counts. As far as the role of physical medicine is concerned, she is right, but to direct this requires publishing of another article.

Dupilumab for treatment‐refractory prurigo nodularis

“…In addition to our case, a total of 24 prurigo nodularis patients have recently been successfully treated with dupilumab (Table 1) and another 16 were treated with dupilumab in an efficacy study by a French group (although there may be some overlap with previously reported patients) [9]. In contrast to our patient, relief from itching was much more rapid in these cases, with improvement within a few weeks [10][11][12][13][14].…”

“…After a full medical examination (including extensive laboratory parameters, sonography of the abdomen, skin biopsies and chest x-ray) no conclusive diagnosis was reached. Based on clinical signs and symptoms with high total IgE levels and an elevated value of the Erlangen atopy score (9) the patient was diagnosed with late onset AD. Treatment with very potent topical corticosteroids (0.5 mg/g clobetasol propionate), narrow band UVB irradiation and oral antihistamines was initiated.…”

Efficacy of dupilumab in prurigo nodularis in elderly patient

“…In the literature, some cases of PN were reported that were successfully treated with dupilumab, showing efficacy in reducing the itch (Beck, Yang, Sekhon, Bhutani, & Liao, ; Calugareanu et al, ; Ferrucci, Tavecchio, Berti, & Angileri, ; Mollanazar, Elgash, Weaver, et al, ; Napolitano et al, ; PH1 & JO2, ; Tanis, Ferenczi, & Payette, ; Zhai et al, ).…”

Erfolgreiche Anwendung von Dupilumab bei therapierefraktärer Prurigo nodularis

“…Der Fallbericht einer IgG4-assozierten Erkrankung mit pruriginösen Nodi zeigte, dass ein erhöhter Prozentsatz an Th2-Zellen und eine Erhöhung der IL-4und IL-13-Produktion auch bei dieser Erkrankung vorliegen kann [7]. Eine rezente Untersuchung zeigte eine gesteigerte [9]. Im Gegensatz zu unserer Patientin war das subjektive Ansprechen (Reduktion des Pruritus) in den meisten Fällen deutlich früher zu beobachten [10][11][12][13][14].…”